Company: SUPN
Filing Date: 2025-11-04
Form Type: 8-K
Source: 0001356576-25-000068
Chunk: 1

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-04
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01

Regulation FD Disclosure.

On November 4, 2025, the Company announced that due to stronger than expected demand for ONAPGO, supplier constraints are impacting the Company’s ability to fully meet this demand. As a result of this supply imbalance, the Company is prioritizing care for patients currently on ONAPGO. This requires pausing delivery to patients who have not yet started ONAPGO. The Company is working to build adequate inventory and resume new patient initiations as soon as possible, and will provide timely updates as progress is made in resolving this supply constraint.

The information in Items 2.02 (including Exhibit 99.1) and Item 7.01 is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing.

This Current Report on Form 8-K contains “forward-looking statements” that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as “believe,” “expect,” “intend,” “may,” “will,” “should,” or “anticipate” or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus’ ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form 8-K are also subject to various risks and uncertainties, including those set forth in Item 1A, “ Risk Factors,” in Supernus’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024 which the Company filed on February 25, 2025,